Hyland's
Product brand
UnclaimedHyland's is a United States–based brand of homeopathic products sold primarily in the United States and Canada.
Last updated August 24, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
Hyland's is a homeopathic consumer-health brand associated with Standard Homeopathic Co. The brand sells homeopathic products in the United States and Canada, operating in the United States through Hyland's Inc and in Canada through Hyland's Homeopathic Canada Inc. Its range has included products positioned for common ailments and symptoms, including infant and children's products, topical or oral remedies, and products marketed for issues such as ear discomfort, sleep, and restless legs. The business traces its origins to 1903, when it was established in Los Angeles as Standard Homeopathic Pharmacy. In 1910, George H. Hyland purchased the business, after which the company adopted the name Standard Homeopathic Company. The Hyland's name became the consumer-facing identity for products associated with the company. The brand expanded into Canada in 1990, giving it a cross-border North American presence while retaining a focus on homeopathic remedies. Hyland's became particularly visible in the children's health category through its teething products. Hyland's Teething Tablets were reported to be the second-most-popular teething product in the United States in 2004. The products later became the subject of significant regulatory and public-health scrutiny because of concerns involving belladonna, an ingredient used in the formulation, and the adequacy of child-resistant packaging. In 2010, the U.S. Food and Drug Administration warned consumers about Hyland's teething products, citing potential toxicity concerns and the absence of child-resistant caps. Hyland's voluntarily recalled the teething-tablet product in both the United States and Canada and introduced a reformulated version with a child-resistant cap in 2011. The teething-product controversy intensified in 2016, when Hyland's stated that it would stop selling Hyland's Teething Tablets in the United States. The FDA said it had received reports involving ten child deaths and approximately 400 adverse events associated with the product. Hyland's disputed the agency's characterization of the reports and described the claims as unsubstantiated, while suggesting that other factors could have contributed to the reported events. In 2017, the FDA said that testing had found inconsistent and sometimes excessive belladonna levels in the product. Hyland's has also faced broader regulatory questions about the labeling and marketing of homeopathic products. An FDA review in 2013 identified numerous products that the agency considered misbranded under provisions of the Federal Food, Drug, and Cosmetic Act. The review included Infant Earache Drops, Restful Legs, Teething Tablets, and other products marketed over the counter for conditions that the agency said could require consultation with a physician. These events illustrate the central tension surrounding the brand: Hyland's has occupied a consumer-health niche built around homeopathic positioning, while regulators have scrutinized the evidence, labeling, dosage consistency, and safety communications associated with those products. The available reference material does not establish a current corporate headquarters, a public stock listing, a named founder distinct from the later purchaser George H. Hyland, or a complete account of the brand's present product assortment. Hyland's remains identified as a Standard Homeopathic Co. division and as a brand serving the United States and Canadian markets.
History
Hyland's developed from a Los Angeles homeopathic business established in 1903 as Standard Homeopathic Pharmacy. The available historical record does not identify the original founder, but it records a major ownership and naming transition in 1910, when George H. Hyland purchased the business. The company was then renamed Standard Homeopathic Company, creating the corporate foundation associated with the later Hyland's consumer brand. For much of its history, the company operated within the homeopathic-products market, selling remedies intended for common symptoms and everyday health concerns. Homeopathic products were generally presented as over-the-counter consumer remedies, allowing the brand to reach customers through retail and other consumer channels rather than relying exclusively on clinical distribution. The reference material does not provide a complete chronology of product introductions or a detailed account of distribution, manufacturing, or ownership changes. Hyland's expanded beyond the United States into Canada in 1990. Its Canadian operations became associated with Hyland's Homeopathic Canada Inc, while the U.S. business operated as Hyland's Inc. The brand is described as a division of Standard Homeopathic Co., linking the consumer-facing Hyland's identity to the broader corporate entity. A particularly important phase in the brand's history involved children's teething products. Hyland's Teething Tablets achieved substantial market visibility and were described as the second-most-popular teething product in 2004. The products later attracted regulatory attention over their use of belladonna and the absence of child-resistant packaging. In 2010, the FDA warned consumers about the products, citing concerns about belladonna toxicity and packaging safety. Hyland's voluntarily recalled the product in the United States and Canada. In 2011, it introduced a reformulated version using a child-resistant cap. The product's regulatory and reputational problems continued. In 2013, the FDA reviewed Hyland's labeling and marketing information and identified numerous products that it considered misbranded under sections of the Federal Food, Drug, and Cosmetic Act. The review covered Infant Earache Drops, Restful Legs, Teething Tablets, and other products. The agency's concern was not limited to ingredients; it also involved the marketing of products for diagnoses or treatments that, in the FDA's view, could require consultation with a physician. In 2016, Hyland's indicated that it would stop selling its teething tablets in the United States. The FDA cited reports of ten child deaths and approximately 400 adverse events associated with the product. Hyland's rejected the agency's characterization, calling the claims unsubstantiated and pointing to alternative explanations for some reported events, including possible allergies and other causes of childhood seizures unrelated to the formulation. In 2017, the FDA stated that its testing had found inconsistent and sometimes excessive belladonna levels in the product. These episodes shaped Hyland's public profile and demonstrate the regulatory risk attached to homeopathic children's products. The brand's history combines long-term participation in the North American homeopathic market with repeated scrutiny over product claims, labeling, formulation consistency, packaging, and safety. The available sources establish the brand's historical origins, Canadian expansion, and major teething-product events, but do not provide enough information to document a complete current product portfolio, current leadership, or precise present-day corporate structure beyond its relationship with Standard Homeopathic Co.
- 2017
FDA reports inconsistent belladonna levels
[1]The FDA confirms that testing found inconsistent and sometimes excessive levels of belladonna in the product.
- 2016
U.S. teething-tablet withdrawal announced
[1]Hyland's indicates that it will stop selling its teething tablets in the United States amid continuing FDA safety concerns.
- 2013
FDA labeling and marketing review
[1]The FDA identifies numerous Hyland's products that it considers misbranded under federal drug law.
- 2011
Reformulated teething product launched
[1]Hyland's begins selling a reformulated teething product with a child-resistant cap.
- 2010
FDA warning and voluntary teething-product recall
[1]The FDA warns consumers about Hyland's teething products, after which Hyland's voluntarily recalls the product in the United States and Canada.
- 2004
Teething Tablets achieve major market visibility
[1]Hyland's Teething Tablets are reported to be the second-most-popular teething product.
- 1990
Entry into Canada
[1]Hyland's begins selling products in Canada through its Canadian operating entity.
- 1910
George H. Hyland purchases the business
[1]George H. Hyland purchases the company, which changes its name to Standard Homeopathic Company.
- 1903
Standard Homeopathic Pharmacy is established
[1]The business that later became associated with Hyland's is founded in Los Angeles as Standard Homeopathic Pharmacy.
Products and positioning
A consumer-health brand positioned around homeopathic remedies for common symptoms and family health needs, particularly children's products. Its positioning has been complicated by regulatory scrutiny of homeopathic claims, product labeling, ingredient consistency, and safety.
Children's homeopathic remedy
Hyland's Teething Tablets
A children's homeopathic product marketed for teething symptoms. It became one of Hyland's best-known offerings and was reported to be the second-most-popular teething product in 2004. The product was recalled after a 2010 FDA warning concerning belladonna and packaging, reformulated with a child-resistant cap in 2011, and later withdrawn from U.S. sale amid continuing regulatory scrutiny.
Infant homeopathic remedy
Infant Earache Drops
A homeopathic product marketed for infant earache-related symptoms. It was among the products examined in the FDA's 2013 review of Hyland's labeling and marketing information. The available material does not establish its current availability or complete formulation.
Homeopathic symptom-relief product
Restful Legs
A Hyland's product marketed for restless-legs symptoms. It was specifically included in the FDA's 2013 review, which raised concerns about marketing products for conditions that may require physician consultation.
Controversies
2017
FDA finding on belladonna content
The FDA stated that testing had found inconsistent and sometimes excessive levels of belladonna in the teething product.
2016
Dispute over reported adverse events and U.S. withdrawal
The FDA cited reports involving ten child deaths and about 400 adverse events associated with Hyland's Teething Tablets. Hyland's disputed the claims as unsubstantiated and announced that it would stop selling the product in the United States.
2013
FDA concerns over product labeling and marketing
An FDA review found numerous Hyland's products that the agency considered misbranded under the Federal Food, Drug, and Cosmetic Act, including products marketed for conditions that could require medical consultation.
2010
FDA warning and recall of teething products
The FDA warned consumers about Hyland's teething products because of concerns about belladonna toxicity and the lack of child-resistant caps. Hyland's voluntarily recalled the product in the United States and Canada.
Brand decisions
2016
Withdrawal of teething tablets from the U.S. marketStrategyBackground
The FDA cited reports of child deaths and adverse events associated with the product, while Hyland's disputed the agency's characterization.
Action taken
Hyland's indicated that it would stop selling Hyland's Teething Tablets in the United States.
Aftermath
The FDA subsequently reported inconsistent and sometimes excessive belladonna levels in testing.
2011
Reformulation and packaging changeGeneration changeBackground
The earlier teething product had been subject to an FDA warning and voluntary recall.
Action taken
Hyland's began selling a reformulated version with a child-resistant cap.
Aftermath
Safety concerns continued to attract regulatory attention in subsequent years.
2010
Voluntary recall of teething tabletsOtherBackground
The FDA warned consumers about potential belladonna toxicity and the lack of child-resistant caps on Hyland's teething products.
Action taken
Hyland's voluntarily recalled the teething-tablet product in both the United States and Canada.
Aftermath
The company later introduced a reformulated version with a child-resistant cap.
Recent events
Hyland’s announces its 2021 Powered Ambassador Team[2]
Hyland’s announced its 2021 Powered Ambassador Team, consisting of 85 marathoners, ultrarunners, triathletes, and cyclists from 27 states representing the brand’s events in the U.S.
Reported
Hyland's launches FLEXmore arthritis pain relief products[3]
Hyland's launched FLEXmore and FLEXmore PM, homeopathic medicines offered in daytime and nighttime formulas for minor arthritis pain relief.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/hylands · Editorial policy · How profiles are compiled